Examinando por Autor "Piskorz, Daniel"
Mostrando 1 - 2 de 2
Resultados por página
Opciones de ordenación
Ítem Guidelines on themanagement of arterial hypertension and related comorbidities in Latin America(International Society of Hypertension, 2017) Burlando, Guillermo; Gonzalez, Claudio; Piskorz, Daniel; Ramirez, Agustín J.; Sanchez, Ramiro A.; Simsolo, Rosa; Voto, Liliana; Alessi, Alexandre; Amodeo, Celso; Araujo Brandáo, Andrea; Baiocchi, Sergio; Barbosa, Eduardo; Barreto Filho, José Augusto; Brandaó Veiga, Paulo César; Brasil, David; Dischinger Miranda, Roberto; Fritsch, Mario; Kalil, Marcio; Machado, Carlos Alberto; Magalhaés Feitosa, Audes; Bolivar Malachias, Marcus Vinicius; Malta, Deborah; Decio Mion, Jr.; Moreno, Heitor; Mota Gomes, Marco; Nobre, Fernando; Nogueira, Armando; Oigman, Wille; Passarelli Jr., Oswaldo; Ribeiro, José Márcio; Santos Póvoa, Rui Manoel; Schmid, Helena; Sebba Barroso, Weimar Kunz; Veiga Jardim, Thiago; Vilela-Martin, José Fernando; Cobos, Leonardo; Lanas, Fernando; Villar Moya, Raul; Accini Mendoza, José Luis; Garcia-Ortiz, Luis Hernando; López-Jaramillo, Patricio; Molina, Dora Ines; Sanchez, Gregorio; Urina – Triana, Miguel; Morales-Salinas, Alberto; Lara, Joffre; Stuardo Wyss, Fernando; Alcocer, Luis; Gonzalez Caamanó, Angel; Parra-Carrillo, Jose Z.; Ortellado, José; Bryce Moncloa, Alfonso; Senclen Santisteban, Segundo; Diaz, Margarita E.; Hernandez Hernandez, Rafael; Lopez, Jesús; Machado, Livia T.; Ponte-Negretti, CarlosABI, ankle-brachial index; ABPM, ambulatory blood pressure monitoring; ACCORD, Action to Control Cardiovascular Risk in Diabetes; ACE-I, angiotensin-converting-enzyme-inhibitors; ARB, AT1 blockers; BP, blood pressure; CARMELA, Cardiovascular Risk Factor Multiple Evaluation in Latin America; CARMEN, Community Actions for Multifactorial Reduction of Non- Communicable Diseases; CCB, calcium channel blocker; CCM, Wagner’s Chronic Care Model; CDC, Chronic Disease Center; CTA, computed tomography angiography; CV, cardiovascular; DALY, disability-adjusted life year; DPP- 4, dipeptidyl-peptidase-4; GLP-1, glucagon-like peptide 1; HBPM, home blood pressure monitoring; HOPE, Heart Outcomes Prevention Evaluation; HOT, Hypertension Optimal Treatment; HT, hypertension; LA, Latin America; LASH, Latin American Society of Hypertension; MRA, magnetic resonance angiography; NCD, noncommunicable disease; OSAS, obstructive apnea–hypopnea syndrome; PAD, peripheral artery disease; PAHO, Pan American Health Organization; RAAS, renin–angiotensin–aldosterone system; RISS, Redes Integradas de Servicios de Salud; SGLUT2, sodium–glucose cotransporter-2; SPRINT, SBP Intervention Trial; UKPDS, United Kingdom Prospective Diabetes Study; VIDA, Veracruz Initiative for Diabetes AwarenessÍtem Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE)(Permanyer, 2021) Ponte-Negretti, Carlos I.; S. Wyss, Fernando; Piskorz, Daniel; D Santos, Raul; Villar, Raul; Lorenzatti, Alberto; López-Jaramillo, Patricio; Toth, Peter; J. Amaro, A. Juan; Rodrigo, Alfonso K.; Lanas, Fernando; Urina-Triana, Miguel; Lara, Jofre; Valdés, T. Osiris; Gomez-Mancebo, José R.; Bryce, Alfonso; Cobos S, Leonardo; Puente-Barragan, Adriana; Ullauri-Solórzano, Vladimir E.; Medina-Palomino, Felix A.; Lozada, Alfredo F.; Duran, Maritza; Berrospi, Percy; Miranda, David; Badimon, Juan J.; R. González, J. José; Libby, PeterHypertension, hyperglycemia, dyslipidemia, overweight, obesity, and tobacco (smoking, chewing, and vaping), together with a pro-inflammatory and procoagulant state, are the main risk factors related to atherosclerotic cardiovascular disease. Objective and methods: A group of experts from the Americas, based on their clinical expertise in cardiology, cardiovascular prevention, and cardiometabolic (CM) diseases, joined together to develop these practical recommendations for the optimal evaluation and treatment of residual CM risk factors in Latin America, using a modified Delphi methodology (details in electronic TSI) to generate a comprehensive CM risk reduction guideline, and through personalized medicine and patient-centered decision, considering the cost-benefit ratio The process was well defined to avoid conflicts of interest that could bias the discussion and recommendations. Results: Residual risk reduction should consider therapeutic options adapt- ed to specific patient needs, based on five treatment objectives: triglyceride-rich lipoproteins, inflammation, impaired glucose metabolism, high blood pressure, and prothrombotic status. Comprehensive control of all CM risk factors should be a priority to deal with this important public health problem and prevent premature deaths. The recommendations in this paper address the evidence-based treatment of CM risk and are intended for clinical application in Latin American countries.